

Biotechnology Colloquium
at
The National Hellenic Research Foundation
ATHENS

Taking Scientific Ideas from Lab to Commerce

Wednesday, 9 July 2008

Program

09:00 – 09:30	Registration At the NHRF Auditorium Entrance Hall
09:30 – 09:45	Opening Remarks Prof. Dimitrios A. Kyriakidis, <i>CEO & Chmn, The National Hellenic Research Foundation</i> Prof. Fragiskos Kolisis, <i>National Technical University of Athens; Director, Institute of Biological Research and Biotechnology, NHRF</i> Prof. Spyros Artavanis-Tsakonas, PhD, <i>Harvard Medical School; President, Fondation Santé</i>
09:45 – 11:00	Panel Session Moderator: Stelios Papadopoulos, PhD, <i>Chairman of the Board, Fondation Santé</i> Seeing the Commercial Relevance of a Scientific Idea Prof. S. Artavanis-Tsakonas, PhD <i>Harvard Medical School; President, Fondation Santé</i> Nurturing a Start-up and Managing Growth George Scangos, Ph.D. <i>President & CEO, Exelixis, Inc</i> Deal Making as a Means of Funding Start-ups Steven Holtzman <i>Co-founder, CEO and Chmn, Infinity Pharmaceuticals</i> Applying Lessons from Pharma to Biotech Jerry Karabelas, PhD <i>Partner, Care Capital</i>
11:00 – 11:30	Coffee Break
11:30 – 12:45	Round Table Discussion with Panelists and Audience The panelists will discuss many issues, including: <ul style="list-style-type: none">• The commercial sustainability of scientific ideas• How the first financing comes about and what are longer term financial strategies• What venture capital is looking for today• The balance between research and market forces• The role of management and the culture of start-ups• Long range planning• Can and should Greece be considered for biotech start-ups
12:45 – 13:00	Closing Remarks Prof. S. Artavanis-Tsakonas, PhD

Panelists

Spyros Artavanis-Tsakonas, PhD is a Professor at the Department of Cell Biology at Harvard Medical School which he joined in 1998. He is also a Professor at the Collège de France, Paris, holding the chair of Developmental Biology and Genetics and the current Director of the Department of Developmental Biology and Genetics at the Curie Institute in Paris. From 1981-1998, Dr. Artavanis-Tsakonas was a Professor in the Departments of Cell Biology and Biology at Yale where he also served as the Director of the Biological Sciences Division and was a Howard Hughes Medical Institute Investigator.

Dr. Artavanis-Tsakonas holds a Masters Degree in Chemistry from the Eidgenössische Technische Hochschule (ETH) in Zurich and a PhD from Cambridge University, England for work carried out at the Medical Research Council Laboratory of Molecular Biology. He is a member of the American Academy of Arts and Sciences, corresponding member of the Athens Academy, and a member of the Cambridge Philosophical society.

Dr. Artavanis-Tsakonas has co-founded the biotechnology companies Exelixis, Inc., Cellzome, Inc., and Anadys Pharmaceuticals, Inc. He is also co-founder and President of Fondation Santé.

Steven H. Holtzman is a founder as well as the Chairman and Chief Executive Officer of Infinity Pharmaceuticals, Inc. Located in Cambridge, MA, Infinity is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients. From early 1994 until 2001, Mr. Holtzman served as the Chief Business Officer of Millennium Pharmaceuticals, Inc. a pioneer in the development and application of modern genetic and genomic technologies to drug discovery.

Prior to joining Millennium and starting in 1986, Mr. Holtzman was a founder and the Executive Vice President of DNX Corporation, the first commercial enterprise devoted to the development of agricultural, biomedical and pharmaceutical applications of transgenic (genetically engineered) animal technology. Prior to DNX, in the early 1980's, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation's first state government program directed at achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970's, he was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K.

Mr. Holtzman co-founded and from 1995 until 2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. From 1996 to 2001, he served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President of the United States and Congress on ethical issues in the biomedical and life sciences. He is a member of the Board of Directors of Anadys Pharmaceuticals, Inc., a Vice Chairman of the Board of Trustees of The Hastings Center for Ethics and the Life Sciences and a Trustee of the Berklee College of Music. Mr. Holtzman received his BA in Philosophy from Michigan State University and his BPhil graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

Argeris (Jerry) Karabelas, PhD has had a distinguished career at senior levels in the global pharmaceuticals industry: he was Chief Executive Officer of Novartis Pharma and prior to that Executive Vice President of Worldwide Pharmaceuticals at SmithKline Beecham. He is currently a Partner of Care Capital LLC, a specialist US healthcare venture capital investment fund, and is Chairman of a number of pharmaceutical and healthcare companies, including Human Genome Sciences, SkyePharma, Vanda, NitroMed, and Inotek. Dr. Karabelas is also a Board Member of Minster and Renovo.

Fragiskos N. Kolisis is Professor of Biotechnology at the National Technical University of Athens (Laboratory of Biotechnology) and Director of the Institute of Biological Research and Biotechnology of the National Hellenic Research Foundation.

His research activities span several areas including: (i) systems biology, functional genomics, metabolomics, and metabolic engineering in studies related with cancer, metabolic syndrome diseases and biotechnology; (ii) industrial biotechnology, specifically biocatalysis in non conventional media (low water content systems, organic solvents, solvent free systems, microemulsion systems, supercritical carbon dioxide) with enzymes, whole cells and catalytic antibodies; and (iii) production, purification, characterization, immobilization and structure/function studies of enzymes.

Prof. Kolisis is Member of the Biotechnology Committee of IUPAC, Member of the Board of the Section of Applied Biocatalysis of European Federation of Biotechnology, Member of the Board of The European Federation for Lipid Science and Technology. He is in the editorial board of several journals related to his subject as *Biocatalysis and Biotransformation* and the *European Journal of Lipid Science and Technology*.

Dimitrios A. Kyriakidis, PhD is a Professor of Biochemistry at the Chemistry Department of the Aristotle University of Thessaloniki, Greece. Prior to that he spent several years (1975-79) at Yale University, Dept. of Pharmacology. He is President of the Hellenic Biochemical and Biophysical Society, Chairman of Chemistry Department, Aristotle Univ. of Thessaloniki, Head of Laboratory of Biochemistry, Chemistry Department, Aristotle Univ. of Thessaloniki and Member of the FEBS Advanced Course Committee. He is now Director of the National Hellenic Research Foundation. His current research interests are on gene cloning and enzyme regulation, metabolic engineering, nanoinprinting, microbial-cell factories and fermentation.

Stelios Papadopoulos, PhD, has been involved in various capacities with biotech and pharma for more than two decades. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where, as an investment banker, he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent thirteen years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.

Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a PhD in biophysics and an MBA in finance, both from New York University.

Dr. Stelios Papadopoulos is a co-founder and chairman of the Board of Directors of Exelixis, Inc., and he is a co-founder and member of the Board of both, Anadys Pharmaceuticals, Inc. and Cellzome, Inc. He is vice-chairman of the Board of Directors of BG Medicine, Inc., a member of the Board of Directors of Neuronix, Inc. and a member of the Scientific Advisory Board of Symphony Capital. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Visitors of Duke University Medical Center and a member of the Board of Directors of the National Marrow Donor Program (NMDP).

George A. Scangos, PhD is President and Chief Executive Officer of Exelixis, Inc. since October 1996. Dr. Scangos began his career on the faculty of the Johns Hopkins University, where he now holds an appointment as Adjunct Professor of Biology. He left Hopkins in 1986 to work for Bayer Corporation, where he held several positions, including Senior Vice President of Research and Development for Bayer's pharmaceutical division, and then President of Bayer Biotechnology.

Dr. Scangos serves on the Boards of Directors of Anadys Pharmaceuticals, Inc., Entelos, Inc., as well as Exelixis. He serves on the Board of Visitors at the University of California, San Francisco School of Pharmacy, the Board of Overseers at the University of California, Davis Medical School, and the Advisory Board for the Cornell University Life Sciences Initiative.

Dr. Scangos received a BA from Cornell University, a PhD in Microbiology from the University of Massachusetts, and was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Frank Ruddle at Yale University.



FONDATION SANTÉ

***Fondation Santé** was established in 2000 as a private foundation operating exclusively for charitable, scientific and educational purposes. The foundation aims to assist in advancing the health and education of those in need, whether individuals, regions or countries.*

For more information about Fondation Santé and our activities, please contact:

info@fondationsante.org

Tel.: + 30 210 6754 831, Fax: + 30 210 6710 666

www.fondationsante.org